Humacyte (HUMA) shares were up over 5% in recent Thursday trading after the company said it received a US patent covering "key aspects" of its bioreactor manufacturing system.
The company said its Symvess acellular tissue-engineered vessel, designed for arterial replacement and repair, is manufactured using the patented system.
The patent lasts until 2040, according to the company.
Price: 3.61, Change: +0.18, Percent Change: +5.10
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。